Polypoidal Choroidal Vasculopathy

23

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

Polypoidal choroidal vasculopathy is an emerging landscape with 23 programs across 9 companies. The most active players are Jiangsu Nhwa Pharmaceutical Co., Ltd., Mateon Therapeutics, Bayer. 6 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

19/100

Mech. Concentration

29/100

Completion Rate

87/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Jiangsu Nhwa Pharmaceutical Co., Ltd.

1 program

Mateon Therapeutics

1 program

Bayer

1 program

Avirmax Biopharma Inc

1 program

Astellas

1 program

Roche

2 programs

Pipeline

Programs by Phase

Analysis

Modality Breakdown

25programs

Small molecule1248%

Monoclonal antibody728%

Protein / enzyme624%

Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed20 · 54%

Unknown status9 · 24%

Recruiting3 · 8%

Terminated2 · 5%

Not yet recruiting1 · 3%

Withdrawn1 · 3%

Other1 · 3%

Clinical Trials

Trial Activity

37 trials

Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial

Recruiting·YYeungnam University College of Medicine·Phase 3·NCT07389980·50 enrolled

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

Recruiting·AAssociation for Innovation and Biomedical Research on Light and Image·Phase 4·NCT06709339·120 enrolled

Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

Recruiting·YYeungnam University College of Medicine·Phase 3·NCT07461441·50 enrolled

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Active, not recruiting·AAvirmax Biopharma Inc·Phase 1/2·NCT06550011·18 enrolled

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT07365371·174 enrolled

OCTA and Polypoidal Choroidal Vasculopathy

Completed·FFederico II University·N/A·NCT04714242·60 enrolled

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Completed·MMateon Therapeutics·Phase 2·NCT01023295·20 enrolled

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed·PPeking Union Medical College Hospital·N/A·NCT05229237·500 enrolled

Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

Completed·Department of Medical Services Ministry of Public Health of Thailand·Phase 4·NCT02860858·50 enrolled

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Completed·—·Phase 4·NCT01871376·25 enrolled

Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

Completed·AAssociation for Innovation and Biomedical Research on Light and Image·Phase 4·NCT02495181·50 enrolled

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Completed· Novartis logo

Novartis·Phase 3·NCT05666804·148 enrolled

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Completed·HHawaii Pacific Health·Phase 1·NCT00424710·17 enrolled

Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Completed·SSun Yat-sen University·N/A·NCT03459144·60 enrolled

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

Completed·FFondation Ophtalmologique Adolphe de Rothschild·N/A·NCT02381730·37 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)